| Abstrakt: |
A recent study conducted in Moscow, Russia, explored the relationship between eosinophilic cells (ECs) and the BRAF V600E mutation in ovarian serous borderline tumors (SBTs). The researchers analyzed 42 samples of SBTs and found that 45% of the cases had the BRAF V600E mutation. The study also found that ECs could serve as a primary screening test for this mutation. However, further research is needed to fully understand the prognostic significance of ECs in SBTs. [Extracted from the article] |
